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Background: Leukemic stem cells (LSCs) are frequently seen as a cause of treatment failure and relapse in patients
with acute myeloid leukemia (AML). Thus, successful new therapeutic strategies for the treatment of AML should
aim at eradicating LSCs. The identification of targets on the cell surface of LSCs is getting more and more attention.
Among these, CD123, also known as the interleukin-3 (IL3)-receptor α chain, has been identified as a potential
immunotherapeutic target due to its overexpression on LSCs in AML as well as on AML blasts, rather than normal
hematopoietic stem cells.
Methods: We constructed a CD123-targeted fusion protein antiCD3Fv-⊿IL3, with one binding site for T cell antigen
receptor (TCRCD3) and the other for CD123, by recombinant gene-engineering technology. Cysteine residues were
introduced into the V domains of the antiCD3Fv segment to enhance its stability by locking the two chains of Fv together
with disulfide covalent bonds. The stability and cytotoxicity of the two fusion proteins were detected in vitro and in vivo.
Results: Both fusion proteins were produced and purified from Escherichia coli 16C9 cells with excellent yields in fully
active forms. High-binding capability was observed between these two fusion proteins and human IL3R, leading to the
specific lysis of CD123-expressing cell lines KG1a; also, mononuclear cells from primary AML patients were inhibited in a
colony forming assay in vitro, presumably by redirecting T lymphocytes in vitro. In addition, they displayed an antileukemic
activity against KG1a xenografts in non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice, especially
disulfide-stabilized (ds)-antiCD3Fv-⊿IL3 for its improved stability.
Conclusions: These results suggest that both fusion proteins display the antileukemic activity against CD123-expressing
cell lines as well as leukemic progenitors in vitro and in vivo, especially ds-antiCD3Fv-⊿IL3. They could be the promising
candidates for future immunotherapy of AML.
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Acute myeloid leukemia (AML) is characterized as the
rapid proliferation of immature myeloid cells in the bone
marrow, resulting in dysfunctional hematopoiesis [1]. Al-
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unless otherwise stated.remission with standard induction chemotherapy, the
majority of them eventually relapse and become resistant
to cytotoxic chemotherapy [2]. Leukemic stem cells
(LSCs) are a common cause of the treatment failure and
the relapse in these patients [3-5], and moreover, their
gene signature are significantly associated with the prog-
nosis of human AML [6]. Therefore, development of
novel therapeutics that can selectively target LSCs is cru-
cial. Recently, many researchers have identified several
AML-associated cell surface phenotypic markers that can
be used as future therapeutic targets [7]. Among them,
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to its overexpression in LSCs in AML rather than normal
hematopoietic stem cells [7,8]. Pre-clinical studies using a
monoclonal antibody targeting CD123 (7G3) or diph-
theria toxin fused to interleukin-3 (DT388IL3) for the
treatment of AML have demonstrated promising antileu-
kemic activity [9-11].
A more potentially efficient approach for cancer pre-
vention and treatment is to manipulate the immune sys-
tem of patients toward cancers cells [12,13]. As we
know, T cells play a pivotal role in tumor immunity by
directly eliminating tumor cells through formation of
synapses of cytotoxic T cell tumor cells [14]. However, T
cells usually cannot effectively identify tumor cells or be-
come anergic because of the complexity of the T cell rec-
ognition mechanism [15]. In the past two decades,
scientists have already taken advantage of T cell potency
in cancer therapy by redirecting their specificity toward
cell surface tumor-associated antigens. For example, bis-
pecific antibodies, by simultaneously recognizing target
antigen on the surface of cancer cells and an activating
receptor on the surface of an immune effector cell, offer
an opportunity to redirect immune effector cells to kill
cancer cells. The other approach is the generation of
chimeric antigen receptors (CAR) by fusing extracellular
antibodies to intracellular-signaling domains. And then,
the CAR-engineered T cells are able to specifically kill
tumor cells in a major histocompatibility complex
(MHC)-independent way. The above two approaches,
both showing promising clinical results, are recognized as
the most effective immuno-biological therapeutics for tu-
mors [16]. Recently, Kuo et al. described a bispecific single-
chain Fv (scFv) immunofusion or BIf to target CD123+
leukemia in vitro that contains an antiCD123 scFv fused at
the N-terminus of human IgG1 hinge-CH2-CH3 and an
antiCD3 scFv fused at C-terminus [17]. While, Mardiros
et al. developed two CD123 CAR-redirected T cells medi-
ated potent effector activities against CD123+ cell lines as
well as primary AML patient samples in vitro and in vivo
[18]. Similarly, Sarah Tettamanti et al. have constructed
CD123-specific CARs that can strongly enhance antiAML
CIK functions [19]. All these works proved the effectiveness
of the CD123-retargeted T cell therapy.
IL3 is a cytokine that promotes the proliferation and dif-
ferentiation of multipotential and committed myeloid and
lymphoid progenitors [20]. The IL3 receptor is a heterodi-
meric structure composed of α and β subunits. The α
chain (CD123) directly binds IL3, and the β subunit is
used to conduct signals [21]. The ligand-receptor-binding
activity is considered to be very potent. To further in-
crease the stability of the ligand-receptor binding, com-
binatorial mutagenesis studies by several laboratories
showed that deletion of eight C-terminal amino acid resi-
dues from IL3 (⊿125-133) or the variant K116W resultedin even higher affinity interactions with IL3R and greater
cytotoxicity against human leukemic stem cells [22-25].
Based on these previous findings, here we constructed
a similar fusion protein antiCD3Fv-⊿IL3 (with the C-
terminal eight amino acids of IL3 deleted, ⊿125-133),
just as bispecific antibodies, that is theoretically capable
of recruiting a polyclonal T cell against LSCs that ex-
press CD123, with one of its arms to the common T cell
signaling protein CD3 and the other to the tumor-
associated antigen CD123 on the target LSCs. Moreover,
to enhance the stability of the fusion protein, a disulfide-
stabilized format (ds-antiCD3Fv-⊿IL3) of this fusion
protein was generated by locking the two chains of Fv
together with disulfide covalent bonds. High-binding
capability was observed between these two fusion pro-
teins and human IL3R, leading to the specific lysis of
CD123-expressing cell lines KG1a; also, mononuclear
cells from primary AML patients were inhibited in a
colony-forming assay in vitro, presumably by redirecting
T lymphocytes in vitro. In vivo, they displayed an antileu-
kemic activity against KG1a xenografts in non-obese dia-
betic/severe combined immunodeficient (NOD/SCID)
mice. And the ds-antiCD3Fv-⊿IL3 demonstrated an even
better performance due to its higher stability. Two advan-
tages make the fusion proteins more effective: first, they
were composed of antiCD3Fv and human recombinant
IL3, resulting in low immunogenicity; second, ⊿IL3, the
ligand of CD123, was employed, demonstrating a better
binding activity than the antigen-antibody binding.Results
Construction and expression of fusion proteins
antiCD3Fv-⊿IL3 and ds-antiCD3Fv-⊿IL3
The nucleotide sequences encoding the fusion proteins were
verified by DNA sequencing. The last eight amino acids at
the C-terminal of IL3 were entirely deleted. In addition, the
Ser-100 of antiCD3VL and Gly-44 of antiCD3VH were suc-
cessfully replaced by cysteines (Figure 1B). The fusion
proteins were expressed by cosecretion of the two poly-
peptide chains (antiCD3VL-⊿IL3 or antiCD3*VL-⊿IL3
and antiCD3VH-⊿IL3-His or antiCD3*VH-⊿IL3-His)
from Escherichia coli 16C9 cells as periplasmic native
proteins (Figure 1A,B). Then, antiCD3VL-⊿IL3 and
antiCD3VH-⊿IL3-His were folded to form fusion protein
antiCD3Fv-⊿IL3 depending on the intermolecular force
(Figure 1C) whereas the two cysteine-mutated polypep-
tide chains antiCD3*VL-⊿IL3 and antiCD3*VH-⊿IL3-His
formed fusion protein ds-antiCD3Fv-⊿IL3 relying on the
disulfide bonds in the periplasmic space (Figure 1D). The
fusion proteins were released from the periplasmic space
of E. coli by osmotic shock and purified by 6 × His-tag af-
finity chromatography. The yields of purified fusion pro-
teins ranged from 1 to 2 mg/L of culture medium.
Figure 1 Expression and purification of the fusion proteins antiCD3Fv-⊿IL3 and the ds-antiCD3Fv-⊿IL3. Schematic of the expression
plasmid for (A) antiCD3Fv-⊿IL3 and (B) ds-antiCD3Fv-⊿IL3, and structure of the fusion proteins for (C) antiCD3Fv-⊿IL3 and (D) ds-antiCD3Fv-⊿IL3.
Note: the drawing is not to scale; asterisk (*) indicates the site of the disulfide bond. The fusion proteins were expressed in E. coli, purified by affinity
chromatography, and analyzed by SDS-PAGE and immunoblotting. (E) Colloidal staining of a SDS-PAGE gel. Lane 1: antiCD3Fv-⊿IL3 in non-reducing
loading buffer; lane 2: ds-antiCD3Fv-⊿IL3 in reducing loading buffer; lane 3: ds-antiCD3Fv-⊿IL3 in non-reducing loading buffer. (F) Immunoblot analysis
of the SDS-PAGE gel with an anti-His-tag antibody. Lane 1: antiCD3Fv-⊿IL3 in non-reducing loading buffer; lane 2: ds-antiCD3Fv-⊿IL3 in reducing
loading buffer; lane 3: ds-antiCD3Fv-⊿IL3 in non-reducing loading buffer.
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PAGE and Western blot. The fusion protein antiCD3Fv-
⊿IL3 was resolved under electrophoretic conditions and
detected as two bands of approximately 30 and 27 kD, cor-
responding to the two polypeptide chains of antiCD3VH-
⊿IL3 and antiCD3VL-⊿IL3, respectively, as anticipated
(Figure 1E). Under reducing conditions, the fusion protein
ds-antiCD3Fv-⊿IL3 was resolved into two proteins bands
consistent with those of antiCD3Fv-⊿IL3. However, under
non-reducing conditions, the fusion protein ds-antiCD3Fv-
⊿IL3 was detected as one band at approximately 57 kD
(Figure 1E). Western blot analysis using an anti-His-tag
antibody validated the existence of the His-tag-containing
fragment and confirmed that the two polypeptide chains of
antiCD3*VL-⊿IL3 and antiCD3*VH-⊿IL3 were linked by
the disulfide bond (Figure 1F).
Dual specificity of the fusion proteins antiCD3Fv-⊿IL3
and ds-antiCD3Fv-⊿IL3
Both antiCD3Fv-⊿IL3 and ds-antiCD3Fv-⊿IL3 bind to
CD123-positive KG1a cells and CD3-positive Jurkat cells
with similar efficiency as their parental monoclonal anti-
bodies CD123 and HIT3a to the respective target cells
(Figure 2A,B,E,F). Furthermore, both fusion proteins
were able to partly reduce the binding efficiency of the
parental monoclonal antibodies HIT3a and CD123
McAb to Jurkat and KG1a, respectively, in a competitivebinding assay (Figure 2C,D,G,H). No significant decrease
in binding activity of ds-antiCD3Fv-⊿IL3 fusion protein
was detected compared to the parental fusion protein
antiCD3Fv-⊿IL3.
Stability of fusion proteins antiCD3Fv-⊿IL3 and ds-antiCD3Fv-
⊿IL3 in vitro
The stability of the fusion proteins in vitro was deter-
mined by analysis of their binding to target cells after in-
cubation in PBS containing 0.2% (w/v) human serum
albumin (HSA) at 37°C for several hours. The results
showed that the binding capacity of the fusion proteins
antiCD3Fv-⊿IL3 was reduced by nearly 50% after incu-
bation for 6 h and 80% for 72 h, while the binding cap-
acity of the ds-antiCD3Fv-⊿IL3 remained more than
90% after 72 h (Figure 3A,B).
Tumor cell lysis mediated by fusion proteins antiCD3Fv-⊿IL3
and ds-antiCD3Fv-⊿IL3
A non-radioactive cytotoxicity assay was performed to de-
termine the ability of the fusion proteins antiCD3Fv-⊿IL3
and ds-antiCD3Fv-⊿IL3 to induce lysis of CD123+ tumor
cells in the presence of pre-activated human T cells. The
fusion proteins antiCD3Fv-⊿IL3 and ds-antiCD3Fv-⊿IL3
appeared to be potent in retargeting T cell lysis of the
CD123-positive KG1a cells (Figure 4A,B,C), whereas
CD123-negative cells THP1 and NB4 were not lysed
Figure 2 (See legend on next page.)
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Figure 2 Analysis of specific binding of fusion proteins antiCD3Fv-⊿IL3 and ds-antiCD3Fv-⊿IL3 to Jurkat and KG1a, as well as the
competitive binding activity with monoclonal antibody HIT3a or CD123. (A, B) Jurkat cells were incubated with fusion proteins (A) antiCD3Fv-⊿IL3
or (B) ds-antiCD3Fv-⊿IL3. (E-F) KG1a cells were incubated with (E) antiCD3Fv-⊿IL3 or (F) ds-antiCD3Fv-⊿IL3. Note: the gate represented the positive
rate of binding of fusion proteins. In the competitive binding assay, (C, D) Jurkat cells were first incubated with ((C): c) antiCD3Fv-⊿IL3 or ((D): c) ds-antiCD3Fv-⊿IL3
and HIT3a. (G, H) KG1a cells were first incubated with ((G): c) antiCD3Fv-⊿IL3 or ((H): c) ds-antiCD3Fv-⊿IL3 and mAb CD123, then incubated with an
FITC-conjugated antimouse IgG. Control groups only reacted with (a.) PBS and (b.) parent mAb IgG. Note: the gate represented the binding rate of the
line of c with monoclonal antibody HIT3a or CD123.
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ingly, the ratio of apoptotic cells in the group of
antiCD3Fv-⊿IL3 (65.633% ± 3.807%) and ds-antiCD3Fv-
⊿IL3 (67.733% ± 3.821%) were increased when combined
with pre-activated human T cells (Figure 4F,G). Additional
movie files show this process of target cell lysis in more
detail (see Additional file 1: Movie 1, Additional file 2:
Movie 2, Additional file 3: Figure S1, and Additional file 4:
Figure S2). Lysis of target cells mediated by the fusionFigure 3 Comparison of the stability of fusion proteins
antiCD3Fv-⊿IL3 and ds-antiCD3Fv-⊿IL3 in vitro. The stability was
determined by testing binding activity of fusion proteins to (A)
CD3-positive Jurkat cells or (B) CD123-positive KG1a cells after incubation
in 0.2% HSA at 37°C for a prolonged time period. Data were normalized
to t0 (initial time), which was set at 100%. The data shown represent the
averages of three independent experiments.protein or ds fusion protein increased in a dose-dependent
manner: increasing either the concentration of fusion pro-
teins or the ratio of effector to target cells resulted in en-
hanced target cell cytotoxicity (Figure 4A,B). The cytotoxic
activity was not enhanced when an equal amount of the
antiCD3/antiCD19 diabody was added, because CD19 was
not expressed on the KG1a cells (Figure 4C). There was no
statistical difference between the parental fusion protein
and the ds fusion protein (500 ng/mL) in mediating the
lysis of KG1a cells at various E:T ratios (Figure 4C).
Cytotoxicity of T cells mediated by the fusion proteins
against AML leukemic progenitors
The peripheral blood mononuclear cells from six newly
diagnosed AML patients were incubated in serum-free
IMDM for 24 h in the presence or absence of different
fusion proteins combined with pre-activated T cells.
Treated and untreated cells were then plated in AML-
colony-forming cell (CFC) assays to evaluate the relative
cytotoxicity of T cells mediated by the fusion proteins
against these leukemic progenitors. AML-CFCs were de-
tected in control (including PBS-treated or fusion pro-
teins without pre-activated T cells) cultures of all six
AML samples, ranging from 112 to 490 AML-CFCs/104
cells (Figure 5A,B,C,D). After 24-h exposure to fusion
proteins with pre-activated T cells, the mean percentages
of kill of AML-CFCs were 53.3% and 52.8%, respectively,
for antiCD3Fv-⊿IL3 and ds-antiCD3Fv-⊿IL3, (range,
33.9% ~ 63.4%) (Figure 5A,E,F). There was no statistical
difference between the parental fusion protein and the
ds fusion protein (500 ng/mL) in mediating the inhib-
ition of colony formation of AML leukemic progenitors
in vitro (Figure 5A). These findings indicate that the two
fusion proteins can preferentially retarget T cells to
AML progenitor cells.
Inhibition of growth of human KG1a xenografts in vivo
We established a NOD/SCID mouse model bearing the
human AML progenitor cell line KG1a to determine
whether the fusion proteins also had an antitumor activ-
ity in vivo. The pathological finding showed KG1a tumor
cells were in diffuse and intensive distribution, which in-
dicated the subcutaneous KG1a xenotransplanted model
was established successfully (Figure 6A). The expression
level of CD123 on the surface of KG1a xenografts
Figure 4 Cytotoxicity of IL2 pre-activated human T cells to KG1a cells in different effector to target (E/T) ratios mediated by different
concentrations of fusion proteins in a non-radioactive cytotoxicity assay. (A) Cytotoxicity of T cells in the presence of antiCD3Fv-⊿IL3. (B)
Cytotoxicity of T cells in the presence of ds-antiCD3Fv-⊿IL3. Concentrations of fusion proteins were different (500, 50, 5 ng/mL). E/T cell ratios
ranged from 25:1 to 3:1. (C) Lysis of target cells by T cells mediated by PBS, ds-antiCD3Fv-⊿IL3, antiCD3Fv-⊿IL3, and the control diabody
antiCD19 × antiCD3. The concentration of all fusion proteins was 500 ng/mL. CD123-negative cell line (D) THP1 and (E) NB4 were included as a
control. (F, G) Ratios of apoptotic cells mediated by fusion proteins (500 ng/mL) combined with pre-activated T cells at E/T ratio of 25:1. PBS and
antiCD19 × antiCD3 are used as a control. **P < 0.01 vs PBS. Data shown are the mean ± SD of three repeated experiments.
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KG1a cell line (77.875% ± 3.090%) (Figure 6B). Two
doses (50 and 100 μg/mouse) of the fusion proteins were
chosen to evaluate their ability to inhibit tumor growth in
NOD/SCID mice. Animals were sacrificed when the tu-
mors had grown to approximately 4,000 mm3 in size. As
shown in Figure 6C, compared to the mice in the control
group (untreated), the mice treated with different dosages
of fusion proteins antiCD3Fv-⊿IL3 or ds-antiCD3Fv-
⊿IL3 combined with pre-activated T lymphocytes showed
a significant dose-related tumor regression. Furthermore,
the ds fusion protein had a better antitumor activity than
the parental fusion protein, when equivalent doses of ds
fusion protein and the parent fusion protein were com-
pared. The ability of tumor regression still exceeded itsparental fusion protein slightly, even with half dose of the
ds fusion protein (Figure 6C).
Discussion
Although current treatment regimens for AML can
achieve a complete remission, most patients will ultim-
ately relapse and die from the disease or complications
associated with the treatment [2], emphasizing the un-
met medical need for novel therapeutics that are more
effective and durable. Recent advances in AML-targeting
immunotherapies including dendritic cell vaccines,
adoptive T cell therapy, and antigen-specific cytotoxic T
lymphocytes open the possibilities for eradicating min-
imal residual diseases which contain chemoresistant
LSCs after chemotherapy [26]. To this end, we chose the
Figure 5 Cytotoxicity of IL2 pre-activated human T cells mediated by the fusion proteins against AML leukemic progenitors in a methylcellulose
colony-forming assay. (A) AML cells from six patients were incubated in serum-free IMDM for 24 h in the presence or absence of different fusion
proteins (500 ng/mL) combined with pre-activated T cells at E/T ratio of 25:1, then plated in AML-CFC assays to evaluate the relative cytotoxicity
of T cells mediated by the fusion proteins against these leukemic progenitors. (B-F) showed typical colonies of different groups. (B) PBS, (C)
antiCD3Fv-⊿IL3, or (D) ds-antiCD3Fv-⊿IL3 alone was used as control group. (E) Cytotoxicity of T cells against leukemic progenitors in the presence of
antiCD3Fv-⊿IL3. (F) Cytotoxicity of T cells against leukemic progenitors in the presence of ds-antiCD3Fv-⊿IL3.
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erentially expressed on AML LSCs compared with nor-
mal hematopoietic stem cells, including CD123, CD44,
CLL-1, CD47 [7], and T cell immunoglobulin mucin-3
(TIM-3) [27], the rationale of its selection being its over-
expression not only by the bulk AML population, but
also by LSCs in 75%–89% of AML patients [28-30]. In
this study, we aimed to develop a fusion protein
antiCD3Fv-⊿IL3 that would direct T cell to specifically
target CD123+ AML cells just like bispecific antibodies.
Since the heavy chain (VH) and the light chain (VL) do-
mains of antiCD3Fv are associated non-covalently, they dis-
sociated relatively easily. To enhance the stability of the
fusion protein, we employed disulfide covalent bonds to
lock the two chains together as we have done before in the
antiPgp × antiCD3 diabody and the antiCD19 × antiCD3
diabody, both of which showed a higher antitumor activ-
ity in animal models [31,32]. As expected, the disulfide-
stabilized antiCD3Fv-⊿IL3 improved the serum stability
by the disulfide cross-linking of the CD3 Fv fragments.
The results showed that ds-antiCD3Fv-⊿IL3 retained
90% activity even after 3 days post incubation at 37°C in
PBS, compared with the parent fusion protein with a t1/2
of 6 h under the same conditions (Figure 3A,B). In
addition, the ds-antiCD3Fv-⊿IL3 had the same antigen-
binding specificity and cytotoxic activity in vitro as the
parent fusion protein (Figure 4A,B). Thus, compared with
the parent fusion protein, the more stable ds-antiCD3Fv-
⊿IL3 may conceivably penetrate deeper into the tumorand stay longer in the tumor, resulting in a greater antitu-
mor activity in vivo (Figure 6C).
The expression of multiple cell surface tumor-
associated antigens on AML cells has been well charac-
terized [7,26,27]. In this work, we have engineered fusion
proteins to redirect T cells to target CD123+ AML cells.
The CD123 is highly expressed by primary AML cells, as
well as LSCs, while displaying limited expression on
hematopoietic stem cells and T cells [7,28,30]. The LSCs
are thought to be spared from chemotherapy and cap-
able of reinitiating the disease. Anne S. Rong et al. have
discovered CD123 and hMICL in combination with
CD34 and CD117 as a universal marker combination for
the detection of minimal residual disease (MRD) of
AML in pre-clinical and clinical settings [33]. Thus,
therapies targeting CD123 aiming at eradicating LSCs
should be the successful novel therapeutic strategy,
which can be applied after the standard induction
chemotherapy to eliminate MRD and reduce recurrence.
As expected, therapies targeting CD123 have showed fa-
vorable safety profiles in phase I trials (ClinicalTrials.gov
ID#NCT00401739 and #NCT00397579). Besides, there
are some other AML antigens which may be potential
targets. For instance, the epithelial mucin, MUC1, is
expressed on primary AML cells and can be recognized
by MUC1-specific cytotoxic T lymphocytes [34]. The
CD47 is identified as an adverse prognostic factor and is
more highly expressed on AML LSC than their normal
counterparts [35]. The TIM-3 antigen is another target
Figure 6 Antitumor effect of fusion proteins antiCD3Fv-⊿IL3 and ds-antiCD3Fv-⊿IL3 in KG1a xenografted NOD/SCID mice. (A) H&E
staining showed the KG1a tumor cells were diffused and in intensive distribution, indicating subcutaneous KG1a xenotransplanted model was
established successfully. (B) The expression level of CD123 on the surface of KG1a xenografts and KG1a cell line were analyzed by FACS. (C) A
mixture of T cells and fusion proteins antiCD3Fv-⊿IL3 or ds-antiCD3Fv-⊿IL3 in different concentrations (50 and 100 μg/mouse) were injected
intravenously 6 days later, when the solid tumors reached 80–100 mm3 in size, once per week for 2 weeks. PBS, antiCD3Fv-⊿IL3, ds-antiCD3Fv-⊿IL3,
and T cells alone, and T cells combined with antiCD19 × antiCD3 diabody, were used as control groups. The size of the xenografts was measured every
3 days. Error bars indicate SD (n = 5). **P < 0.01 vs PBS.
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pression on a subset of T cells may result in autolysis of
T cells [36], making it a non-ideal target for a T-cell-
based therapy.
Anticancer immunity involves both the innate and adap-
tive immune systems, yet it is generally considered that
CD8+ cytotoxic T lymphocytes (CTL) are the most potent
antitumor effector cells [37]. But in fact, researches have
been acutely aware that tumor cells can develop multiple
escape mechanisms, such as a physical barrier avoiding in-
filtration of effector cells and lower expression level of
MHC as well as secretion of cytokines that indirectlyinhibit T cell proliferation [37]. Therefore, specific re-
agents for T cell retargeting have been developed to make
T cells kill tumors more effectively. Among different ap-
proaches, the most potent therapeutics are the use of bis-
pecific antibodies and CARs to redirect T cell specificity
toward cell surface tumor-associated antigens. CARs,
known as chimeric immune receptors, should be inserted
into effector cells, and then, they can redirect effector cell
specificity toward cell surface tumor-associated antigens
independent of the T cell receptor (TCR)-defined specifi-
city and in a MHC-independent manner. This technology
has shown an excellent efficacy in pre-clinical studies as
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may also be dangerous, such as, the activation of effector
cells can be too strong to lead to a cytokine storm and even
to death [40]. Therefore, clinical use of CARs is still limited
by the complexity of engineering processes and further im-
provement needs to be done. The efficacy of bispecific
antibodies has already been validated in pre-clinical studies
and has shown promising results in clinical trials, for ex-
ample, antiCD19 × antiCD3 BiTE Ab called blinatumomab
in phase II trial (ClinicalTrials.gov ID#NCT01207388) has
shown an 80% complete molecular response rate and pro-
longed leukemia-free survival in patients with minimal re-
sidual B-lineage acute lymphoblastic leukemia [41].
Besides, there are some other bispecific antibodies under
clinical trials, such as antiEpCAM× antiCD3 for epithelial
cancers or gastric cancer in phase II/III trial, antiHER-2 ×
antiCD3 for metastatic or advanced breast cancer in
phase II trial [16]. To target CD123, Shu-Ru Kuo et al.
have engineered a CD123 × CD3 bispecific scFv immuno-
fusion to target CD123+ LSCs in vitro, which contained
an antiCD123 scFv fused at the N-terminus of human
IgG1 hinge-CH2-CH3, and an antiCD3 scFv fused at C-
terminus; the molecular weight of 140 kDa would affect
their penetration into tumor tissue [17]. Then, in our
work, we successfully constructed a smaller fusion protein
antiCD3Fv-⊿IL3 and its disulfide-stabilized antiCD3Fv-
⊿IL3, both displaying a potent antileukemic activity, espe-
cially for the ds-antiCD3Fv-⊿IL3 in vivo. Compared with
CD123-specific CAR T cells, this approach is less efficient
against AML LSCs but more convenient and controllable
in the clinical application. To enhance the curative effect
of antiCD3Fv-⊿IL3, it is possible to develop a multi-
epitope reagent, because its manner of T cell activation is
dependent on T cell receptor functional signals which may
be defective in cancer patients.
Moreover, due to the overexpression of CD123 (IL3Rα)
on AML leukemic stem cells, researchers have exploited
drugs that fuse IL3 to efficient toxin or chemotherapeutics
to eradicate human AML stem cells. Among these fusion
proteins, the DT388IL3 showed cytotoxicity to LSCs
in vitro and in vivo with minimal damage to normal tis-
sues [10,11]. Currently, phase II clinical trial has been
completed. Furthermore, researchers also found that the
variant DT388IL3 (△125-133) showed an enhanced bind-
ing to the human IL3R and greater cytotoxicity to human
AML cell lines and LSCs than the wild-type DT388IL3
[42]. Following the same way, our laboratory constructed
and expressed the fusion protein antiCD3Fv-IL3 and dis-
covered the fusion protein was unstable and could easily
break in the end of the C-terminal (data not shown), which
was also consistent with some combinatorial mutagenesis
studies [22-25]. So we engineered the fusion protein
antiCD3Fv-⊿IL3 (⊿125-133) and its disulfide-stabilized
antiCD3Fv-⊿IL3, which combined the advantages of boththe specificity of humoral immunity and the efficiency
of cellular immunity compared with fusion proteins
DT388IL3.
Conclusion
Fusion proteins antiCD3Fv-⊿IL3 and disulfide-stabilized
antiCD3Fv-⊿IL3, especially the latter one, display the
antileukemic activity against CD123-expressing cell lines
as well as leukemic progenitors in vitro and in vivo. They
could be the promising candidates for future immuno-
therapy of AML. In the future, we will explore various
methods to enhance T lymphocyte activities against
leukemic cells of AML, such as in combination with
chemotherapeutics [43] or developing a multi-epitope
reagent with ligands of costimulatory molecules.
Methods and material
Cell lines
Hybridoma cell lines producing the antiCD3 monoclonal
antibody HIT3a (IgG2a, к) were established and main-
tained at the Institute of Hematology, Chinese Academy
of Medical Sciences (Tianjin, China) as described previ-
ously [44]. The human acute T cell leukemia cell line
Jurkat, human acute myelogenous leukemia progenitor
cell line KG1a, human acute monocytic cell line THP1,
and human acute promyelocytic leukemia cell line NB4
were all derived from our laboratory. Jurkat, THP1, and
NB4 were maintained in RPMI 1640 and KG1a in
IMDM media (Gibco, Grand Island, NY) containing 10%
fetal bovine serum (Gibco, Grand Island, NY). All the
cells were cultured at 37°C with 5% CO2.
Construction of plasmids of the antiCD3Fv-⊿IL3 or
disulfide-stabilized antiCD3Fv-⊿IL3
The fragments of antiCD3VL and antiCD3*VL (contain-
ing a cysteines at position Ser-100 of CD3VL) containing
the restriction enzyme site MluI and the G4S linker were
obtained by polymerase chain reaction (PCR) from the
plasmid pLH-T3a-19a and pLH-T3a*-19a [32], using the
primer pairs P1/P2 (Table 1, all primers were synthe-
sized by Invitrogen Life Technologies, USA), respect-
ively. The antiCD3VH and antiCD3*VH (containing a
cysteines at position Gly-44 of CD3VH) segments con-
taining the restriction enzyme site MluI and the G4S
linker were generated similarly by PCR from the plasmid
pLH-19a-T3a and pLH-19a-T3a* [32], respectively, using
the primer pairs P5/P6. The fragment of ⊿IL3 (the end
of eight amino acids were deleted) was obtained by PCR
from cDNA of human peripheral blood mononuclear
cells, using the primer pairs P3/P4 (including the restric-
tion enzyme site NheI and the G4S linker) or P3/P7
(both containing the G4S linker). The His tag and the
restriction enzyme site SphI were introduced into the
PCR products by re-amplification with the primer pairs
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of antiCD3VL-G4S-⊿IL3 or antiCD3*VL-G4S-⊿IL3 and
antiCD3VH-G4S-⊿IL3-His or antiCD3*VH-G4S-⊿IL3-
His through the complementary sequences of the G4S
linker. The resulted fusion products were cleaved with
the restriction enzymes MluI/NheI and MluI/SphI and
subsequently cloned into the pLH-T3a-19a and pLH-
19a-T3a vectors to generate plasmids pLH-CD3VL or
CD3*VL-⊿IL3 and pLH-CD3VH or CD3*VH-⊿IL3-His.
The latter vector has contained the restriction enzymes
site NheI and the E. coli heat-stable enterotoxin II (stII)
signal at the 5′ end of antiCD3VH or antiCD3*VH-⊿IL3-
His. The abovementioned vectors were cleaved with the
restriction enzymes MluI/NheI and NheI/SphI, respect-
ively, to generate two fragments of antiCD3VL or
antiCD3*VL-⊿IL3 and stII-antiCD3VH or antiCD3*VH-
⊿IL3-His and then subcloned into the MluI/SphI sites
of the expression vector pCANTAB5E (GE healthcare,
Little Chalfont, Buckinghamshire, UK).
The expression and purification of fusion proteins
The soluble fusion protein was extracted from E. coli
strain 16C9 containing the expression plasmids and
purified by methods described previously [31]. The puri-
fied fusion proteins were subjected to electrophoresis in
12% polyacrylamide gels and stained with Coomassie bril-
liant blue to confirm their purity, respectively. In addition,
an identical gel was transferred onto a PDVF membrane
and a Western blot analysis was performed using a mouse
anti-His-tag antibody IgG (Tiangen Biotech, Beijing,
China) and goat antimouse antibody IgG conjugated with
horseradish peroxidase (Union Stem Cell & Gene engin-
eering, Tianjin, China). Purified fusion proteins were kept
under a sterile condition and stored at −80°C.
Flow cytometric analysis
The CD123-positive cell line KG1a and the CD3-positive
cell line Jurkat were employed for analysis of bindingactivity of the purified proteins by flow cytometry
(FACS LSRII, Becton Dickinson Bioscience, San Jose,
CA). Briefly, 1 × 106 cells in 100-μL phosphate-
buffered saline (PBS) were incubated with various fu-
sion proteins (20 μg/mL) for 1 h at 4°C. After being
washed three times with cold PBS, the cells were incu-
bated with 100-μL anti-His antibody IgG at 10 μg/mL
for 1 h, followed by incubation with 20 μL of FITC-
labeled rabbit antimouse antibody IgG (Institute of
Hematology, Chinese Academy of Medical Sciences,
Tianjin, China) for an additional 30 min. The stained
cells were washed and analyzed by flow cytometry. In a
competitive binding assay, 1 × 106 KG1a cells in 100-
μL PBS were first incubated with 20 μg/mL of various
fusion proteins for 1 h at 4°C, then incubated with par-
ent McAb IgG (CD123 McAb for KG1a and HIT3a for
Jurkat cells, respectively) for 1 h at 4°C. After being
washed three times with cold PBS, the cells were incu-
bated with an FITC-conjugated rabbit antimouse IgG
for 30 min. The stained cells were then analyzed by
flow cytometry.
Stability assays in vitro
Fusion proteins were incubated at a concentration of
20 μg/mL in PBS containing 0.2% (w/v) HSA at 37°C for
a variety of time periods. The remaining binding activity
of the fusion proteins incubated with KG1a or Jurkat
cells were detected using flow cytometry.Isolation of PBMC, sorting, and stimulation of T
lymphocytes
With informed consent obtained, human peripheral
blood mononuclear cells (PBMCs) were isolated from
peripheral blood taken from healthy volunteers or AML
patients using Ficoll-Hypaque density-gradient centrifu-
gation (Institute of Hematology, Chinese Academy of
Medical Sciences, Tianjin, China). The clinical pro-
cesses were approved by the Ethics Committees of the
Hospital of Blood Disease, Peking Union Medical Col-
lege. The mononuclear cell layer was removed, washed
twice, and cell number counted, then the cell suspen-
sion was depleted of monocytes by adherence to plastic
flasks for 2 h. Non-adherent cells were used for T cell
isolation by fluorescence-activated cell sorter (FACS).
PBMCs (1 × 108) in 500-μL PBS were incubated with
15 μL of allophycocyanin (APC)-conjugated antihuman
CD3 mAbs (clone UCHT1,BD Pharmingen, San Diego,
CA) at 4°C for 60 min and then washed twice with PBS.
T cells sorted out by FACS (AriaIII, Becton Dickinson
Biosciences) were cultured in a complete RPMI 1640
medium containing 10% FCS and 50 IU/mL of IL2 for
48 h to activate T lymphocytes.
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The efficacy of fusion proteins in mediating T cell cyto-
toxicity was evaluated by the calcein-release assay [45].
The CD123-positive cell line KG1a and the CD123-
negative cell line THP1 and NB4 were prepared as target
cells. Equal concentrations of antiCD3 × antiCD19 dia-
body were established as control. The experimental and
calculating methods were proceeded as described previ-
ously [31].Methylcellulose colony-forming assay
To evaluate inhibition of colony formation, the mono-
nuclear cells from peripheral blood of an AML patient
were cultured in serum-free IMDM for 24 h in the pres-
ence or absence of different fusion proteins (500 ng/mL)
combined with pre-activated T cells at the effector-target
cell ratio of 3:1. Then, cells were plated in 96-well plates
at 10,000 cells/25 μL or 40,000 cells/25 μL in Methocult
H4434. And the numbers of colonies were scored after
15–20 days of culture. All the treatments were per-
formed in triplicate.Growth inhibition of human KG1a xenografts in vivo
All animal procedures were approved by Ethics Com-
mittee on the use and care of animals, Chinese Acad-
emy of Medical Science. Female 6-week-old NOD/SCID
mice (Cancer Institute, Chinese Academy of Medical
Sciences, Beijing, China) were inoculated subcutane-
ously with 2 × 107 KG1a cells into armpits, 1 day after
the application of total body irradiation (300 cGy).
Treatment was initiated at 6 days post-tumor inocula-
tion, when the solid tumors reached 80–100 mm3 in
size. Each group consisted of seven mice at least. Mice
were treated with two different doses (50, 100 μg/
mouse) of the two fusion proteins, combined with pre-
activated T cells (5 × 106 cells/mouse) in PBS via the tail
vein, every 7 days for 2 weeks. Mice received intraven-
ous injections of various fusion proteins (100 μg/mouse)
alone, pre-activated T cells (5 × 106 cells/mouse), a com-
bination of antiCD3 × antiCD19 (100 μg/mouse) dia-
body and pre-activated T cells (5 × 106 cells/mouse), or
PBS as control. Growing tumors were measured using a
vernier caliper in two perpendicular dimensions every
3 days, and the tumor volumes were calculated using
the following formula: V = (L ×W2)/2, where L repre-
sents the longest axis of the tumors (in mm) and W rep-
resents the axis perpendicular to L (in mm). Mice were
sacrificed by cervical dislocation under anesthesia when
the tumors reached 4,000 mm3 in size. The mean tumor
volume of the treatment groups and control groups
were evaluated by Student’s t-test with SPSS18.0 soft-
ware (SPSS, Cary, NC).Additional files
Additional file 1: Movie 1. The process of cytotoxicity of IL2 pre-activated of
human T cells to KG1a cells mediated by the fusion protein antiCD3Fv-⊿IL3
was observed by Nikon Ti-e cell-imaging system. Cells (5 × 103 KG1a per well)
were plated in a 96-well plate, followed by added IL2 pre-activated human T
cells at effector-target cell ratio of 25:1 in the presence of antiCD3Fv-⊿IL3
(500 ng/mL). After a transient laid aside in the incubator, the plate was
observed by Nikon Ti-e cell-imaging system. Several fields were chosen
and a picture was taken for each every 1 h. The actual speed of the
movie plays at roughly 500 ms/frame. In the movie, the larger cells were
KG1a cells and the smaller cells were T cells. The process of recruitment
of T cell to tumor cells and the lysis of tumor cells was observed.
Additional file 2: Movie 2. The process of cytotoxicity of IL2 pre-activated
of human T cells to KG1a cells mediated by the fusion protein ds-antiCD3Fv-⊿IL3
was observed by Nikon Ti-e cell-imaging system. The same as antiCD3Fv-⊿IL3, we
can observe the process of recruitment of T cell to tumor cells and the lysis of
tumor cells in this movie. The larger cells were KG1a cells and the smaller cells
were T cells.
Additional file 3: Figure S1. The typical screenshots of movie 1 (A, B,
C, D) displayed the cytotoxicity of T cells mediated by the fusion protein
antiCD3Fv-⊿IL3 in one field at different time points. The blue areas
showed the typical process of cytotoxicity. The larger cells were KG1a
cells and the smaller cells were T cells. The fusion protein antiCD3Fv-⊿IL3
appeared to be potent in retargeting T cell lysis of the KG1a cells.
Additional file 4: Figure S2. The typical screenshots of movie 2 (A, B,
C, D) displayed the cytotoxicity of T cells mediated by the fusion protein
ds-antiCD3Fv-⊿IL3 in one field at different time points. The blue areas
showed the typical process of cytotoxicity. The same as antiCD3Fv-⊿IL3,
ds-antiCD3Fv-⊿IL3 also appeared to be potent in retargeting T cell lysis
of the KG1a cells.
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